Bluebird Bio (BLUE) saw its loss widen to $77.02 million, or $2.07 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $42.92 million, or $1.18 a share. Revenue during the quarter grew 17.22 percent to $1.55 million from $1.32 million in the previous year period.
Operating loss for the quarter was $78.14 million, compared with an operating loss of $43.13 million in the previous year period.
"In recent months, we have made important advances in our gene therapy transduction and manufacturing processes, translational research and clinical development that will be critical for us to successfully bring LentiGlobin drug product to patients with transfusion-dependent -thalassemia (TDT) and severe sickle cell disease (SCD). This includes implementing a new LentiGlobin manufacturing process that has been shown in vitro to consistently improve the percentage of cells transduced and vector copy number, and making a number of changes to the protocol for our ongoing severe SCD study that we believe have the potential to improve patient outcomes. We look forward to sharing initial clinical data from these improvements in 2017," said Nick Leschly, chief bluebird.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
